AssetMark Inc
CLDX icon

AssetMark Inc’s Celldex Therapeutics CLDX Stock Holding History

AssetMark Inc’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$681 Hold
21
– – ﹤0.01% 3326
2026
Q2 		$781 Hold
21
– – ﹤0.01% 3194
2026
Q1 		$666 Buy
+21
New +$572 ﹤0.01% 3122
2024
Q4 		– Sell
-1
Closed -$34 – 2603
2024
Q3 		$34 Hold
1
– – ﹤0.01% 2229
2024
Q2 		$37 Buy
+1
New +$38 ﹤0.01% 2069

Other funds holding CLDX

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
TSP Capital Management Group
TSP Capital Management Group Summit, New Jersey $397M AUM 31.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Mirador Capital Partners
Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

AssetMark Inc's CLDX Position: Q3 2026 in Review

AssetMark Inc held its Celldex Therapeutics (CLDX) position steady in Q3 2026 at 21 shares worth $681. The position accounts for ﹤0.01% of the portfolio, ranked #3326.

AssetMark Inc first reported a position in CLDX in Q2 2024 and has held it in 5 quarters since. The position peaked at $781 in Q2 2026. 70 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.

  • AssetMark Inc held 21 shares of Celldex Therapeutics worth $681 as of Q3 2026.
  • AssetMark Inc left its Celldex Therapeutics share count unchanged in Q3 2026.
  • Celldex Therapeutics made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #3326 holding.
  • AssetMark Inc first reported a position in Celldex Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • AssetMark Inc's Celldex Therapeutics position peaked at $781 in Q2 2026.
  • 70 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.